123 related articles for article (PubMed ID: 37806113)
1. Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients.
Mirjačić Martinović K; Vuletić A; Tišma Miletić N; Besu Žižak I; Milovanović J; Matković S; Jurišić V
Transl Oncol; 2023 Dec; 38():101799. PubMed ID: 37806113
[TBL] [Abstract][Full Text] [Related]
2. Circulating IL-6 is associated with disease progression in BRAFwt metastatic melanoma patients receiving anti-PD-1 therapy.
Mirjačić Martinović K; Vuletić A; Tišma Miletić N; Matković S; Gavrilović D; Ninković A; Jurišić V; Babović N
J Clin Pathol; 2024 Apr; 77(5):343-351. PubMed ID: 36754615
[TBL] [Abstract][Full Text] [Related]
3. Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy.
Zhao N; Yi Y; Cao W; Fu X; Mei N; Li C
Front Oncol; 2022; 12():923531. PubMed ID: 36091125
[TBL] [Abstract][Full Text] [Related]
4. Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients.
Gérard A; Doyen J; Cremoni M; Bailly L; Zorzi K; Ruetsch-Chelli C; Brglez V; Picard-Gauci A; Troin L; Esnault VLM; Passeron T; Montaudié H; Seitz-Polski B
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088741
[TBL] [Abstract][Full Text] [Related]
5. Serum IL-5 and IFN-
Zhao Q; Bi Y; Sun H; Xiao M
Dis Markers; 2021; 2021():5526885. PubMed ID: 34239620
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
Feun LG; Li YY; Wu C; Wangpaichitr M; Jones PD; Richman SP; Madrazo B; Kwon D; Garcia-Buitrago M; Martin P; Hosein PJ; Savaraj N
Cancer; 2019 Oct; 125(20):3603-3614. PubMed ID: 31251403
[TBL] [Abstract][Full Text] [Related]
7. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.
de Miguel-Perez D; Russo A; Gunasekaran M; Buemi F; Hester L; Fan X; Carter-Cooper BA; Lapidus RG; Peleg A; Arroyo-Hernández M; Cardona AF; Naing A; Hirsch FR; Mack PC; Kaushal S; Serrano MJ; Adamo V; Arrieta O; Rolfo C
Cancer; 2023 Feb; 129(4):521-530. PubMed ID: 36484171
[TBL] [Abstract][Full Text] [Related]
8. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.
Wang Y; Zou J; Li Y; Jiao X; Wang Y; Zhuo N; Gao M; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Shen L; Zhang H; Lu Z
Front Immunol; 2022; 13():987568. PubMed ID: 36159840
[TBL] [Abstract][Full Text] [Related]
9. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.
Tyan K; Baginska J; Brainard M; Giobbie-Hurder A; Severgnini M; Manos M; Haq R; Buchbinder EI; Ott PA; Hodi FS; Rahma OE
Cancer Immunol Immunother; 2021 Aug; 70(8):2209-2221. PubMed ID: 33481042
[TBL] [Abstract][Full Text] [Related]
10. The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors.
Wang M; Zhai X; Li J; Guan J; Xu S; Li Y; Zhu H
Front Immunol; 2021; 12():670391. PubMed ID: 34367136
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study.
Yuan M; Zhu Z; Mao W; Wang H; Qian H; Wu J; Guo X; Xu Q
Front Oncol; 2021; 11():683502. PubMed ID: 34692475
[TBL] [Abstract][Full Text] [Related]
12. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.
Sanmamed MF; Perez-Gracia JL; Schalper KA; Fusco JP; Gonzalez A; Rodriguez-Ruiz ME; Oñate C; Perez G; Alfaro C; Martín-Algarra S; Andueza MP; Gurpide A; Morgado M; Wang J; Bacchiocchi A; Halaban R; Kluger H; Chen L; Sznol M; Melero I
Ann Oncol; 2017 Aug; 28(8):1988-1995. PubMed ID: 28595336
[TBL] [Abstract][Full Text] [Related]
13. Association between serum levels of 12 different cytokines and short-term efficacy of anti-PD-1 monoclonal antibody combined with chemotherapy in advanced gastric cancer.
Qi Q; Peng Y; Zhu M; Zhang Y; Bao Y; Zhang X; Zhang J; Liu Y
Int Immunopharmacol; 2023 Jan; 114():109553. PubMed ID: 36516540
[TBL] [Abstract][Full Text] [Related]
14. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
Link J
Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
[TBL] [Abstract][Full Text] [Related]
15. Changes of IL-6 And IFN-γ before and after the adverse events related to immune checkpoint inhibitors: A retrospective study.
Zhang X; Lu X; Yu Y; Tan K; Cui H
Medicine (Baltimore); 2022 Nov; 101(46):e31761. PubMed ID: 36401365
[TBL] [Abstract][Full Text] [Related]
16. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.
Akbar S; Raza A; Mohsin R; Kanbour A; Qadri S; Parray A; Zar Gul AR; Philip A; Vijayakumar S; Merhi M; Hydrose S; Inchakalody VP; Al-Abdulla R; Abualainin W; Sirriya SA; Al-Bozom I; Uddin S; Khan OM; Mohamed Ibrahim MI; Al Homsi U; Dermime S
Front Immunol; 2022; 13():1097117. PubMed ID: 36741391
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients.
Wu D; Liu Y; Pang N; Sun M; Wang X; Haridia Y; Zhao F; Qin Y; Fan W; Guo X; Ding J
Medicine (Baltimore); 2019 Oct; 98(43):e17608. PubMed ID: 31651870
[TBL] [Abstract][Full Text] [Related]
18. Identification of Robust Biomarkers for Early Predicting Efficacy of Subcutaneous Immunotherapy in Children With House Dust Mite-Induced Allergic Rhinitis by Multiple Cytokine Profiling.
Xie S; Fan R; Tang Q; Cai X; Zhang H; Wang F; Xie S; Gao K; Zhang J; Xie Z; Jiang W
Front Immunol; 2021; 12():805404. PubMed ID: 35095890
[TBL] [Abstract][Full Text] [Related]
19. Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Mao XC; Yang CC; Yang YF; Yan LJ; Ding ZN; Liu H; Yan YC; Dong ZR; Wang DX; Li T
Front Immunol; 2022; 13():884592. PubMed ID: 36072577
[TBL] [Abstract][Full Text] [Related]
20. Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors.
Schindler H; Lusky F; Daniello L; Elshiaty M; Gaissmaier L; Benesova K; Souto-Carneiro M; Angeles AK; Janke F; Eichhorn F; Kazdal D; Schneider M; Liersch S; Klemm S; Schnitzler P; Stenzinger A; Sültmann H; Thomas M; Christopoulos P
Front Oncol; 2022; 12():1010660. PubMed ID: 36387148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
